Clearance pathways of soluble immune complexes in the pig. Insights into the adaptive nature of antigen clearance in humans.
Efficient delivery of immune complexes (ICs) to the mononuclear phagocytic system, and subsequent IC processing, may prevent their potentially harmful effects in other tissues and may also be important in the development of humoral immune responses. In mice, rabbits, and primates, the liver and spleen are the main sites of IC clearance. It has been demonstrated previously that the pulmonary capillaries in the pig are lined with macrophages and that certain particulates, including bacteria, localize to this organ. In this study, we used gamma scintigraphy to explore the sites and kinetics of clearance of soluble IC comprising 123I-labeled hepatitis B surface Ag (HBsAg):porcine anti-HBsAg in the Large White pig. At t = 10 min after i.v. injection, 43 +/- 5% (mean +/- SE) IC localized in the lungs, and 36 +/- 6% counts in the liver. At t = 85 min, values were: lungs, 15 +/- 4% and liver, 29 +/- 2%. Findings were similar following intraarterial injection. Complement depletion resulted in more rapid initial IC clearance (t1/2 = 5 min), reduced lung uptake (23 +/- 3% at 10 min), and impaired IC catabolism. In normal animals, 5 to 7% injected IC bound to PBMCs, but no E binding was seen. A fall in PBMC numbers (46 to 59% of baseline), was observed following IC injection. These findings contrast with our previous observations using analogous IC in humans, in which we did not observe any change in peripheral blood leukocyte counts consequent upon complex processing, suggesting that in humans, Es may function as a buffering system for complement-bearing IC in the circulation, preventing their interaction with leukocytes bearing complement and FcR, and the potential activation of these cells.
D000818:Animals; D000936:Antigen-Antibody Complex / Q000378:metabolism*; D003169:Complement Inactivator Proteins / Q000008:administration & dosage; D004546:Elapid Venoms / Q000008:administration & dosage; D006510:Hepatitis B Antibodies / Q000276:immunology*; D006514:Hepatitis B Surface Antigens / Q000276:immunology*; D006801:Humans; D007275:Injections, Intravenous; D007457:Iodine Radioisotopes; D008099:Liver / Q000378:metabolism; D008168:Lung / Q000378:metabolism; D010599:Pharmacokinetics; D013552:Swine
D000936:Antigen-Antibody Complex; D003169:Complement Inactivator Proteins; D004546:Elapid Venoms; D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D007457:Iodine Radioisotopes; C016310:cobra venom factor